Intramuscular interferon beta-1a is effective in Japanese patients with relapsing–remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions
Background and objective: Interferon beta (IFNβ) is standard therapy for multiple sclerosis (MS). The efficacy of intramuscular (IM) IFNβ-1a (AVONEX®) was assessed in 25 Japanese patients with relapsing–remitting MS (RRMS). Methods: Patients with RRMS not previously treated with IFNβ or other diseas...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2012-12, Vol.18 (12), p.1782-1790 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1790 |
|---|---|
| container_issue | 12 |
| container_start_page | 1782 |
| container_title | Multiple sclerosis |
| container_volume | 18 |
| creator | Saida, Takahiko Itoyama, Yasuto Tashiro, Kunio Kira, Jun-ichi Hao, Qi |
| description | Background and objective:
Interferon beta (IFNβ) is standard therapy for multiple sclerosis (MS). The efficacy of intramuscular (IM) IFNβ-1a (AVONEX®) was assessed in 25 Japanese patients with relapsing–remitting MS (RRMS).
Methods:
Patients with RRMS not previously treated with IFNβ or other disease-modifying therapies were included in this 36-week study. The primary outcome was the average total number of gadolinium-enhanced lesions detected on four brain MRI scans during the last 12 weeks of 24 weeks’ treatment with IM IFNβ-1a 30 μg once weekly compared with the number during the 12-week pre-treatment period. Lesions were counted by blinded investigators.
Results:
IM IFNβ-1a significantly decreased the median number of gadolinium-enhanced lesions from 2.5 to 0.3 (p < 0.0001) compared with pre-treatment values. The median number of new gadolinium-enhanced lesions also decreased significantly from 2.0 to 0.3 (p = 0.0002). Serum neopterin was induced in a manner similar to that observed previously in a Caucasian RRMS population. No new adverse events occurred during the study.
Conclusion:
This first study of IM IFNβ-1a in Japanese patients with RRMS demonstrated a level of efficacy similar to that reported in Caucasian patients based on an assessment of pre-treatment and post-treatment gadolinium-enhanced lesions. |
| doi_str_mv | 10.1177/1352458512442261 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1282834232</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458512442261</sage_id><sourcerecordid>2846847131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-2bad10a8c80eab64104d721848d6509e3faf74e0afcc46b6904f82eadd5f82513</originalsourceid><addsrcrecordid>eNp1kd9qFTEQxhdRbK3eeyUBEbxZTbLZf96VYvVIRRC9Xmazk9OUbHbNJJXe-Q59LZ_CJzHlHK0UvJoh329mvswUxVPBXwnRtq9FVUtVd7WQSknZiHvFoVBtW_K-5fdznuXyRj8oHhFdcM7btqofFgdSql6Kih8WPzc-BpgT6eQgMOsjBoNh8WzECKUAZomhMaijvcSssw-wgkdCtkK06COx7zaes4AOVrJ---vHdcDZxphzNicX7eqQkXa5K1l6w4CtAcsYEOKc69klBkrEbh_0Mq8QLGUTFNN0xRbDtjAtznqb5hL9OXiNE_v4ecPGANmTQ7KLp8fFAwOO8Mk-HhVfT99-OXlfnn16tzk5Pit11dexlCNMgkOnO44wNkpwNbVSdKqbmpr3WBkwrUIORmvVjE3PlekkwjTVOdaiOipe7vquYfmWkOIwW9LoXF7MkmgQspNdpWQlM_r8DnqxpOCzu0wpIbkQfZcpvqN03hEFNMMa7AzhahB8uLn0cPfSueTZvnEaZ5z-Fvw5bQZe7AEgDc6EvDRLt1yTv1zLJnPljiPY4j_u_jf4N8VGw2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1241201198</pqid></control><display><type>article</type><title>Intramuscular interferon beta-1a is effective in Japanese patients with relapsing–remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Saida, Takahiko ; Itoyama, Yasuto ; Tashiro, Kunio ; Kira, Jun-ichi ; Hao, Qi</creator><creatorcontrib>Saida, Takahiko ; Itoyama, Yasuto ; Tashiro, Kunio ; Kira, Jun-ichi ; Hao, Qi ; Interferon Beta-1a Multiple Sclerosis Study Group of Japan ; the Interferon Beta-1a Multiple Sclerosis Study Group of Japan</creatorcontrib><description>Background and objective:
Interferon beta (IFNβ) is standard therapy for multiple sclerosis (MS). The efficacy of intramuscular (IM) IFNβ-1a (AVONEX®) was assessed in 25 Japanese patients with relapsing–remitting MS (RRMS).
Methods:
Patients with RRMS not previously treated with IFNβ or other disease-modifying therapies were included in this 36-week study. The primary outcome was the average total number of gadolinium-enhanced lesions detected on four brain MRI scans during the last 12 weeks of 24 weeks’ treatment with IM IFNβ-1a 30 μg once weekly compared with the number during the 12-week pre-treatment period. Lesions were counted by blinded investigators.
Results:
IM IFNβ-1a significantly decreased the median number of gadolinium-enhanced lesions from 2.5 to 0.3 (p < 0.0001) compared with pre-treatment values. The median number of new gadolinium-enhanced lesions also decreased significantly from 2.0 to 0.3 (p = 0.0002). Serum neopterin was induced in a manner similar to that observed previously in a Caucasian RRMS population. No new adverse events occurred during the study.
Conclusion:
This first study of IM IFNβ-1a in Japanese patients with RRMS demonstrated a level of efficacy similar to that reported in Caucasian patients based on an assessment of pre-treatment and post-treatment gadolinium-enhanced lesions.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458512442261</identifier><identifier>PMID: 22492130</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adolescent ; Adult ; Asian Continental Ancestry Group ; Biological and medical sciences ; Brain - pathology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Gadolinium ; Humans ; Image Enhancement ; Immunologic Factors - administration & dosage ; Immunologic Factors - adverse effects ; Immunologic Factors - pharmacokinetics ; Injections, Intramuscular ; Interferon beta-1a ; Interferon-beta - administration & dosage ; Interferon-beta - adverse effects ; Interferon-beta - pharmacokinetics ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - pathology ; Neopterin - analysis ; Neurology ; Young Adult</subject><ispartof>Multiple sclerosis, 2012-12, Vol.18 (12), p.1782-1790</ispartof><rights>The Author(s) 2012</rights><rights>2014 INIST-CNRS</rights><rights>SAGE Publications © Dec 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-2bad10a8c80eab64104d721848d6509e3faf74e0afcc46b6904f82eadd5f82513</citedby><cites>FETCH-LOGICAL-c395t-2bad10a8c80eab64104d721848d6509e3faf74e0afcc46b6904f82eadd5f82513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458512442261$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458512442261$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26721526$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22492130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saida, Takahiko</creatorcontrib><creatorcontrib>Itoyama, Yasuto</creatorcontrib><creatorcontrib>Tashiro, Kunio</creatorcontrib><creatorcontrib>Kira, Jun-ichi</creatorcontrib><creatorcontrib>Hao, Qi</creatorcontrib><creatorcontrib>Interferon Beta-1a Multiple Sclerosis Study Group of Japan</creatorcontrib><creatorcontrib>the Interferon Beta-1a Multiple Sclerosis Study Group of Japan</creatorcontrib><title>Intramuscular interferon beta-1a is effective in Japanese patients with relapsing–remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background and objective:
Interferon beta (IFNβ) is standard therapy for multiple sclerosis (MS). The efficacy of intramuscular (IM) IFNβ-1a (AVONEX®) was assessed in 25 Japanese patients with relapsing–remitting MS (RRMS).
Methods:
Patients with RRMS not previously treated with IFNβ or other disease-modifying therapies were included in this 36-week study. The primary outcome was the average total number of gadolinium-enhanced lesions detected on four brain MRI scans during the last 12 weeks of 24 weeks’ treatment with IM IFNβ-1a 30 μg once weekly compared with the number during the 12-week pre-treatment period. Lesions were counted by blinded investigators.
Results:
IM IFNβ-1a significantly decreased the median number of gadolinium-enhanced lesions from 2.5 to 0.3 (p < 0.0001) compared with pre-treatment values. The median number of new gadolinium-enhanced lesions also decreased significantly from 2.0 to 0.3 (p = 0.0002). Serum neopterin was induced in a manner similar to that observed previously in a Caucasian RRMS population. No new adverse events occurred during the study.
Conclusion:
This first study of IM IFNβ-1a in Japanese patients with RRMS demonstrated a level of efficacy similar to that reported in Caucasian patients based on an assessment of pre-treatment and post-treatment gadolinium-enhanced lesions.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Asian Continental Ancestry Group</subject><subject>Biological and medical sciences</subject><subject>Brain - pathology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Gadolinium</subject><subject>Humans</subject><subject>Image Enhancement</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Immunologic Factors - adverse effects</subject><subject>Immunologic Factors - pharmacokinetics</subject><subject>Injections, Intramuscular</subject><subject>Interferon beta-1a</subject><subject>Interferon-beta - administration & dosage</subject><subject>Interferon-beta - adverse effects</subject><subject>Interferon-beta - pharmacokinetics</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - pathology</subject><subject>Neopterin - analysis</subject><subject>Neurology</subject><subject>Young Adult</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kd9qFTEQxhdRbK3eeyUBEbxZTbLZf96VYvVIRRC9Xmazk9OUbHbNJJXe-Q59LZ_CJzHlHK0UvJoh329mvswUxVPBXwnRtq9FVUtVd7WQSknZiHvFoVBtW_K-5fdznuXyRj8oHhFdcM7btqofFgdSql6Kih8WPzc-BpgT6eQgMOsjBoNh8WzECKUAZomhMaijvcSssw-wgkdCtkK06COx7zaes4AOVrJ---vHdcDZxphzNicX7eqQkXa5K1l6w4CtAcsYEOKc69klBkrEbh_0Mq8QLGUTFNN0xRbDtjAtznqb5hL9OXiNE_v4ecPGANmTQ7KLp8fFAwOO8Mk-HhVfT99-OXlfnn16tzk5Pit11dexlCNMgkOnO44wNkpwNbVSdKqbmpr3WBkwrUIORmvVjE3PlekkwjTVOdaiOipe7vquYfmWkOIwW9LoXF7MkmgQspNdpWQlM_r8DnqxpOCzu0wpIbkQfZcpvqN03hEFNMMa7AzhahB8uLn0cPfSueTZvnEaZ5z-Fvw5bQZe7AEgDc6EvDRLt1yTv1zLJnPljiPY4j_u_jf4N8VGw2Q</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Saida, Takahiko</creator><creator>Itoyama, Yasuto</creator><creator>Tashiro, Kunio</creator><creator>Kira, Jun-ichi</creator><creator>Hao, Qi</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20121201</creationdate><title>Intramuscular interferon beta-1a is effective in Japanese patients with relapsing–remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions</title><author>Saida, Takahiko ; Itoyama, Yasuto ; Tashiro, Kunio ; Kira, Jun-ichi ; Hao, Qi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-2bad10a8c80eab64104d721848d6509e3faf74e0afcc46b6904f82eadd5f82513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Asian Continental Ancestry Group</topic><topic>Biological and medical sciences</topic><topic>Brain - pathology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Gadolinium</topic><topic>Humans</topic><topic>Image Enhancement</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Immunologic Factors - adverse effects</topic><topic>Immunologic Factors - pharmacokinetics</topic><topic>Injections, Intramuscular</topic><topic>Interferon beta-1a</topic><topic>Interferon-beta - administration & dosage</topic><topic>Interferon-beta - adverse effects</topic><topic>Interferon-beta - pharmacokinetics</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - pathology</topic><topic>Neopterin - analysis</topic><topic>Neurology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saida, Takahiko</creatorcontrib><creatorcontrib>Itoyama, Yasuto</creatorcontrib><creatorcontrib>Tashiro, Kunio</creatorcontrib><creatorcontrib>Kira, Jun-ichi</creatorcontrib><creatorcontrib>Hao, Qi</creatorcontrib><creatorcontrib>Interferon Beta-1a Multiple Sclerosis Study Group of Japan</creatorcontrib><creatorcontrib>the Interferon Beta-1a Multiple Sclerosis Study Group of Japan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saida, Takahiko</au><au>Itoyama, Yasuto</au><au>Tashiro, Kunio</au><au>Kira, Jun-ichi</au><au>Hao, Qi</au><aucorp>Interferon Beta-1a Multiple Sclerosis Study Group of Japan</aucorp><aucorp>the Interferon Beta-1a Multiple Sclerosis Study Group of Japan</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intramuscular interferon beta-1a is effective in Japanese patients with relapsing–remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>18</volume><issue>12</issue><spage>1782</spage><epage>1790</epage><pages>1782-1790</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background and objective:
Interferon beta (IFNβ) is standard therapy for multiple sclerosis (MS). The efficacy of intramuscular (IM) IFNβ-1a (AVONEX®) was assessed in 25 Japanese patients with relapsing–remitting MS (RRMS).
Methods:
Patients with RRMS not previously treated with IFNβ or other disease-modifying therapies were included in this 36-week study. The primary outcome was the average total number of gadolinium-enhanced lesions detected on four brain MRI scans during the last 12 weeks of 24 weeks’ treatment with IM IFNβ-1a 30 μg once weekly compared with the number during the 12-week pre-treatment period. Lesions were counted by blinded investigators.
Results:
IM IFNβ-1a significantly decreased the median number of gadolinium-enhanced lesions from 2.5 to 0.3 (p < 0.0001) compared with pre-treatment values. The median number of new gadolinium-enhanced lesions also decreased significantly from 2.0 to 0.3 (p = 0.0002). Serum neopterin was induced in a manner similar to that observed previously in a Caucasian RRMS population. No new adverse events occurred during the study.
Conclusion:
This first study of IM IFNβ-1a in Japanese patients with RRMS demonstrated a level of efficacy similar to that reported in Caucasian patients based on an assessment of pre-treatment and post-treatment gadolinium-enhanced lesions.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>22492130</pmid><doi>10.1177/1352458512442261</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2012-12, Vol.18 (12), p.1782-1790 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1282834232 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adolescent Adult Asian Continental Ancestry Group Biological and medical sciences Brain - pathology Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Female Gadolinium Humans Image Enhancement Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - pharmacokinetics Injections, Intramuscular Interferon beta-1a Interferon-beta - administration & dosage Interferon-beta - adverse effects Interferon-beta - pharmacokinetics Magnetic Resonance Imaging Male Medical sciences Middle Aged Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Neopterin - analysis Neurology Young Adult |
| title | Intramuscular interferon beta-1a is effective in Japanese patients with relapsing–remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A03%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intramuscular%20interferon%20beta-1a%20is%20effective%20in%20Japanese%20patients%20with%20relapsing%E2%80%93remitting%20multiple%20sclerosis:%20a%20pre-treatment%20versus%20treatment%20comparison%20study%20of%20gadolinium-enhanced%20MRI%20brain%20lesions&rft.jtitle=Multiple%20sclerosis&rft.au=Saida,%20Takahiko&rft.aucorp=Interferon%20Beta-1a%20Multiple%20Sclerosis%20Study%20Group%20of%20Japan&rft.date=2012-12-01&rft.volume=18&rft.issue=12&rft.spage=1782&rft.epage=1790&rft.pages=1782-1790&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458512442261&rft_dat=%3Cproquest_cross%3E2846847131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1241201198&rft_id=info:pmid/22492130&rft_sage_id=10.1177_1352458512442261&rfr_iscdi=true |